Project Grant R21AI188103
Award Date
7/3/25
Completion Date
6/30/27
Dollars Obligated
$429K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award of $634,984 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the role of a specific B cell subset, termed BND2, in the rapid progression of type 1 diabetes (T1D) in young-onset patients. The primary objectives are to: 1) determine the mechanism by which these autoreactive B cells become activated and break anergy, 2) assess their potential to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $120,255 to the University of Colorado-Denver to investigate the mechanisms by which antigen-specific immunotherapy can suppress autoreactive T cells and prolong islet graft survival in a mouse model of autoimmune diabetes. The research aims to determine the differentiation and functional states of antigen-specific CD4...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $287,000 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, which runs from April 2025 to March 2027, aims to determine whether genetic mutations that alter IL-17 signaling contribute to the etiology of autoimmune diabetes. The research will use in vitro and in vivo approaches to understand...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $380,000 to the University of Miami to develop a bifunctional RNA therapeutic called PS03. The goal is to use PS03 to modulate PD-L1 expression specifically on B cells in order to induce T cell exhaustion and halt the autoimmune attack in type 1 diabetes. The award period runs from August 1, 2025 to July 31, 2026....
This $310,897 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a first-in-class, islet-targeted antibody therapeutic for Type 1 Diabetes (T1D). The award supports preclinical development and validation activities for this novel antibody therapy, including establishing proof-of-principle for its islet-homing capability, therapeutic...
This federal Project Grant award, R01DK140781, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The $1,449,016 award aims to use advanced immunoproteomics technologies to comprehensively screen for microbial infections associated with increased or decreased risk of islet autoimmunity and type 1 diabetes in children participating in the TEDDY study. The project...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $235,403 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Johns Hopkins University. The funding will support the development of a membrane-reconstituted ZNT8 biosensor to detect cell-surface ZNT8 autoantibodies in the peripheral blood of patients with type-1 diabetes. This novel bioanalytical tool aims to enable the early detection of islet...
This federal Cooperative Agreement award, with a total funding amount of $1,207,770.00 and an award date of January 1, 2025, was granted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award will support research to investigate the role of genetically-controlled thymic epithelial cell (TEC) and hematopoietic stem cell (HSC) abnormalities in driving the development...
This Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), focuses on investigating the role of lymph node stromal cells in maintaining peripheral tolerance and reducing autoimmunity in type 1 diabetes. The primary awardee, The Trustees of Columbia University in the City of New York, will receive $602,531 to conduct research aimed at: Evaluating...